Dry Eye Syndrome Treatment Market Trends, Drivers, Strategies, Applications and Competitive Landscape Till 2026

Dry
eye syndrome (DES) is also known as keratisis sicca and
keratoconjunctivitis sicca. Patients suffering from DES show damage
to the ocular surface, instability in the tear film, and visual
disturbance. Tear film covers the ocular surface, which is made up of
three intertwined layers, a superficial lipid layer, produced by
meibomian glands assist in reducing tear evaporation and uniform tear
spreading, middle thick aqueous layer produced from lacrimal glands,
and the innermost hydrophilic mucin layer produced from goblet cells
of conjunctiva and epithelium of ocular surface.
The two most common
types of DES are DES associated with Sjogren syndrome (SS) and DES
unassociated with SS. DES can also be classified as aqueous
deficiency dry eye and evaporative dry eye disorder. Patients with
aqueous tear deficiency (ATD) often suffer from SS if they have shown
symptoms of connective tissue disease (CTD) or xerostomia in past.
Patients with primary SS showed evidence of autoimmune disease with
high presence of ocular surface disease, ATD and serum
autoantibodies. According to TearScience Inc., in 2012, around 86% of
the patients in Europe and the U.S. were suffering from DES showed
symptoms of Meibomian Gland Dysfunction (MGD, blockage of meibomian
glands). The blockage causes less secretion of oil in the tears,
which results in evaporation of tears too quickly.
The most common
symptoms associated with DES are ocular irritation, photophobia,
blurry vision, mucoid discharge, ocular dryness, itching, and
excessive tearing. DES is diagnosed through tests such as the
Schirmer test, tear film osmolarity, tear meniscus height, tear
ferning test, measurement of tear break up time, and staining of
corneal and conjuctivital epithelium with lissamine green and
fluorescein or rose bengal. Topical anti-inflammatory agents
(cyclosporine and corticosteroids), omega 3 fatty acids,
immunosuppressant, umbilical cord serum, artificial tear substitutes
and gels, emulsions, and ointments are the common agents used for
treatment of DES. Advanced options for the treatment of DES include
conjunctival flap, mucous membrane grafting, lateral tarsorrhaphy,
salivary gland duct transposition, amniotic membrane contact lens
therapy, and prosthetic replacement of the ocular surface ecosystem
(PROSE) lens therapy.
The global dry eye
syndrome treatment market is primarily driven by growing geriatric
population coupled with high prevalence of dry eye syndrome and
growth in awareness about the diagnosis and treatment of the disease.
However, the stringent drug approvals, expirations of the blockbuster
drugs patents, and lack of skilled ophthalmologists are restraining
the growth of DES market. According to National Health and Wellness
Survey in 2013, approximately 16.4 million people are suffering from
DES, which accounts for 6.8% of the total population of the U.S.
Prevalence of DES increases with age, 2.7% for 18 - 34 age group and
18.6% for more than 75 age group were reported to be suffering from
DES. The prevalence of DES is higher in women (8.8%) as compared to
men (4.5%). According to the National Eye Institute, in the U.S the
annual cost of treating DES including prescription drugs is US $3.84
billion.
Global Dry Eye
Syndrome Treatment Market Taxonomy
On the basis of
product type, the global dry eye syndrome treatment market is
segmented into:
Cyclosporine
Oral
Corticosteroid
Artificial Tears
Omega
Supplements
Punctual Bags
Removable
Bags
Dissolvable
Bags
Others
On the basis of
disease type, the global dry eye syndrome treatment market is
segmented into:
Evaporative Dry
Eye Syndrome
Aqueous Dry Eye
Syndrome
On the basis of
distribution channel, the global dye eye syndrome treatment market is
segmented into:
Retail
Pharmacies
Hospital
Pharmacies
Online
Pharmacies
Request For
Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1173
High healthcare
expenditure and increasing R&D activities in the DES treatment
market is expected to propel growth of DES market in North America
Growing geriatric
population coupled with high prevalence of dry eye syndrome owing to
lifestyle disorders are contributing factors for the growth of DES
market in the North America region.
Asia Pacific region
is emerging in DES treatment market due to large pool of patient
population. According to the regional population based study
published in All India Ophthalmological Society, in 2012, the
prevalence of DES was 40.8% with mild symptoms and 31.7% with MGD.
Global dry eye
syndrome treatment market is oligopolistic in nature with few players
holding majority of the share. Various strategies are adopted by
market players such as new product launches, acquisitions, and
agreements in order to retain market position. In September, 2017,
Johnson and Johnson Vision, acquired TearScience Inc., a medical
device manufacturer for treating MGD. This acquisition expanded the
company’s eye health portfolio. In April 2017, Allergan received
marketing approval from FDA for its TrueTear Intranasal Tear
Neurostimulator.
Some of the major
players operating in the global dry eye syndrome treatment market are
Allergan, Novartis AG., Otsuka Pharmaceutical Co. Ltd., Valent
Pharmaceuticals, Johnson and Johnson Vision, Acadia Pharmaceuticals,
Allostera Pharma, I-Med Pharma Inc., Santen Pharmaceuticals Co. Ltd.,
AFT pharmaceuticals, Novaliq GmBh, and Auven therapeutics.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment